Treatment-related adverse effects with TKIs in patients with advanced or radioiodine refractory differentiated thyroid carcinoma: a systematic review and meta-analysis

BACKGROUND: Tyrosine kinase inhibitors (TKIs) have been administered to advanced or radio-iodine refractory differentiated thyroid carcinoma (RR-DTC) patients for years. We performed a pooled analysis to explore the frequency of severe adverse effects in advanced or RR-DTC patients treated with sora...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Shi-Tong, Ge, Jun-Na, Luo, Jing-Yi, Wei, Zhi-Gang, Sun, Bai-Hui, Lei, Shang-Tong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6388981/
https://www.ncbi.nlm.nih.gov/pubmed/30863162
http://dx.doi.org/10.2147/CMAR.S191499

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6388981/
https://www.ncbi.nlm.nih.gov/pubmed/30863162
http://dx.doi.org/10.2147/CMAR.S191499

Ejemplares similares